IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lee et al. Art Unit: 1652

Patent No.: 7.572.599 Examiner: I. H. Chowdhury

Issue Date: August 11, 2009 Conf. No.: 5508

Application No.: 10/665,374 Filed: September 16, 2003

Title: METALLOPROTEASE ACTIVATION OF MYOSTATIN, AND

METHODS OF MODULATING MYOSTATIN ACTIVITY

CERTIFICATE OF CORRECTIONS BRANCH

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322

Sir:

The undersigned attorney of record petitions the Commissioner for Patents for a Certificate of Correction correcting a typographical error in a patent, incurred through the fault of the Office in the Claims of the above issued patent. It is respectfully requested that the Claims be amended as follows.

In Re Application of:
Lee et al.
Application Serial No.: 7,572,599
Issued: August 11, 2009

Page 2

PATENT Attorney Docket No. JHU1800-3

Please amend Claim 1 as follows:

"1. A method of modulating myostatin activation, comprising contacting a latent myostatin complex comprising a myostatin pro-peptide and a myostatin C-terminal fragment, and a metalloprotease that can cleave the myostatin pro-peptide, wherein the metalloprotease is mammalian bone morphogenic protein-1 (BMP-1), with an agent that increases or decreases proteolytic cleavage of the pro-peptide by the metalloprotease, wherein the myostatin complex comprises SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, and wherein the agent is a peptide consisting of SEQ ID NO: 9, thereby modulating myostatin activation."

Accompanying this Request are completed Forms PTO/SB/44 to be included with the issued patent.

In view of the above statements, it is respectfully requested that a Certificate of Correction of United States Patent Number 7,572,599 be issued.

No fee is deemed necessary with the filing of this paper as the mistake in a patent, incurred through the fault of the Office. However, the Commissioner is further authorized to charge any fees that may be due in connection with the filing of this paper, or credit any overpayment to Deposit Account No. <u>07-1896</u>, referencing the above-referenced Attorney docket number.

Respectfully submitted,

Date: January 29, 2010

Antony M. Novom, J.D. Registration No. 45,517 Telephone: (858) 638-6641 Facsimile: (858) 677-1465

DLA PIPER LLP (US) 4365 Executive Drive, Suite 1100 San Diego, CA 92121-2133 USPTO CUSTOMER NO. 28213

WEST/21872978.1 331323-000269

PTO/SB/44 (09-07) Approved for use through 08/31/2010. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7572599

APPLICATION NO.: 10/665,374

ISSUE DATE: : August 11, 2009

INVENTOR(S) : Se-Jin Lee, Alexandra C. McPherron, Daniel S. Greenspan, William N. Pappano, Neil Wolfman,

Kathy Tomkinson

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

1. A method of modulating myostatin activation, comprising contacting a latent myostatin complex comprising a myostatin pro-peptide and a myostatin C terminal fragment, and a metalloprotease that can cleave the myostatin pro-peptide, wherein the metalloprotease is mammalian bone morphogenic protein-1 (BMP-1), with an agent that increases or decreases proteolytic cleavage of the pro-peptide by the metalloprotease, wherein the myostatin complex comprises SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, and wherein the agent is a neptide consisting of SEQ ID NO: 9. thereby modulating myostatin activation.

MAILING ADDRESS OF SENDER (Please do not use customer number below): Antony M. Novom, J.D., DLA Piper LLP (US)

4365 Executive Drive, Suite 1100, San Diego, California 92121

858 638 6641

This collection of information is required by 37 OFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentially is governed by 3 U.S.C. 122 and 37 OFR 1.14. This collection is entirely to take 1.0 burst occupied; including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you greater less from another suggesterors for reducing the bases. Any comment office, U.S. Operational for the complete of the com

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.